Zomedica Corp. — fact timeline

Zomedica Corp. reported the first quarter ended March 31, 2026 results: revenue $8.8 million.

“Zomedica Announces Record First Quarter Revenue of $8.8 Million”

Michael Zuehlke was appointed as Vice President of Finance and Corporate Controller at Zomedica Corp..

“Until a Chief Financial Officer is hired to replace Mr. Jordan, Mr. Michael Zuehlke, Vice President of Finance and Corporate Controller of Zomedica Inc. will assume operational responsibility for accounting and finance matters.”

Scott Jordan resigned as Chief Financial Officer at Zomedica Corp..

“Effective April 25, 2025, Scott Jordan resigned from employment as Chief Financial Officer of Zomedica Corp.”

Zomedica Corp. reported full year 2024 results: revenue $31 to $35 million. Guidance reaffirmed.

“For the full year 2024, the Company continues to expect full year revenue in the range of $31 to $35 million, an increase of approximately 39% at the high end of the range, over full year 2023 revenue of $25.2 million.”

Zomedica Corp. reported the quarter ended March 31, 2024 results: revenue $6.3 million, net income $9.2 million, EPS $0.01 per share.

“Revenue for the three months ended March 31, 2024, was $6.3 million, compared to $5.5 million for the three months ended March 31, 2023, an increase of $0.8 million or approximately 14%. The increase was driven by growth in both operating segments: Therapeutic Devices and Diagnostics. Cost of revenue was $2.1 million, compared to $1.6 million for the three months ended March 31, 2023, an increase of $0.5 million. Margins remained strong at 66%, in line with expectations. Adjusting for our Qorvo Biotechnologies LLC (“QBT”) acquisition and other one-time items brings our gross margin for the quarter to over 69%, in line with recent levels. Operating expenses were $14.5 million, compared to $11.3 million for the three months ended March 31, 2023, an increase of $3.2 million or 28%. When adjusted for one-time, non-recurring charges, and expenses associated with ongoing QBT operations, total operating expenses grew just over 20% on a comparative basis. We continue to expect total operating”

Zomedica Corp. reported full year 2024 results: revenue $31 to $35 million. Guidance reaffirmed.

“Zomedica continues to expect full year revenue in the range of $31 to $35 million”

Zomedica Corp. reported the year ended December 31, 2023 results: revenue $25.2 million.

“X-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity ANN ARBOR, MI / ACCESSWIRE / April 1, 2024 / Zomedica Corp.”

Zomedica Corp. reported the fourth quarter ended December 31, 2023 results: revenue $7.3 million.

“Revenue for the fourth quarter of 2023 grew 19% to $7.3 million”

Zomedica Corp. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v)).

“March 13, 2024, Zomedica Corp. (the “Company”) announced that it was continuing its dialogue with the NYSE American LLC (the “NYSE American”) regarding next steps associated with the deficiency letter (the “Letter”) the Company received from NYSE American on September 12, 2023. As reported in a prior Form 8-K, the Letter indicated that the Company was not in compliance with the NYSE American continued listing standards set forth in Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) because the Company’s common shares were trading for a substantial period of time at a l”

Zomedica Corp. shareholders rejected Approve an amendment to the Company's Articles of Incorporation to effect a share consolidation (reverse split) at a ratio of 80-for-1 at the 2024-02-28 meeting.

“Approve an amendment to the Company's Articles of Incorporation (“Articles”) to effect a share consolidation (reverse split) of our issued and outstanding Common Shares at a ratio of 80-for-1, the implementation and timing of which shall be subject to the discretion of our Board of Directors (the “Share Consolidation Proposal”). The final votes cast on the Share Consolidation Proposal were as follows: For: 136,067,529 39.44% Against: 206,789,223 59.95% Abstain: 2,109,080 0.61%”